Physician profile
Allison Bardowell
NPI 1285122853
$992.41
in general payments reported to CMS, 2019-2025
16 companies · $156 in 2025
The $156 reported for 2025 was more than what a typical Neuromusculoskeletal Medicine, Sports Medicine provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $221 · 2023: $40.33 · 2024: $398 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.14 | 2022-2025 | |
| Novo Nordisk INC | $135.05 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.11 | 2023-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $130.97 | 2021 | |
| Lilly USA, LLC | $93.92 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $41.38 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $37.11 | 2024 | Gvoke Hypopen |
| Alkermes, INC. | $36.48 | 2024-2025 | Aristada, Lybalvi |
| Ucb, INC. | $29.08 | 2021 | |
| Neurocrine Biosciences, INC. | $27.08 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $25.07 | 2024 | Spravato |
| Dexcom, INC. | $20.68 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $17.99 | 2023 | Trintellix |
| Eisai INC. | $17.25 | 2021 | |
| Insulet Corporation | $17.09 | 2024 | Omnipod |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $16.01 | 2025 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Bardowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.